新闻稿

Intrasense presents its AI innovations at the SIRM congress in Italy

10 6 月 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in SIRM, the congress organized by the Italian Society of Medical and Interventional Radiology, to be held from June 20 to 23 in Milan (Italy).

发现更多

Intrasense announces CE certification of Liflow® to the new European regulation (MDR)

29 4 月 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, is proud to announce that the company has obtained CE certification under MDR (European Union Medical Device Regulation 2017/745), for the first version of its Liflow® solution.

发现更多

Intrasense announces the appointment of Jérôme Thiebaud as Chief Business Officer

24 4 月 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.

发现更多

Liflow®: an innovative AI-enhanced solution to optimize oncology follow-up

16 4 月 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.

发现更多

Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI

8 4 月 2024

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG and the Icobrain™ AI developed by Icometrix. This market launch is a major step in the two companies' joint development plan and the realization of their growth ambitions.

发现更多

Intrasense presents its innovations at the European Congress of Radiology (ECR) 2024

26 2 月 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its participation at the ECR from February 28 to March 3, in Vienna (Austria).

发现更多

Intrasense announces the certification of Myrian® to the new European regulation (MDR)

21 2 月 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, is proud to announce that the company has obtained the new CE certification under MDR (European Union Medical Device Regulation 2017/745), authorizing the marketing of the latest version of its Myrian® solution.

发现更多

Intrasense announces annual revenue for 2023

8 2 月 2024

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian® (the "Company"), today announced its 2023 consolidated IFRS revenue (uncertified) at Group level.

发现更多

Intrasense and the ICM sign a partnership to optimize a new solution dedicated to oncology

6 2 月 2023

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, has joined forces with the Montpellier Cancer Institute (ICM) through a partnership aimed at validating and then deploying its new platform dedicated to oncology in real-life situations, with the objective of using it in clinical routine.

发现更多

Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

11 1 月 2023

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions ("Intrasense" or the "Company") announces that the Guerbet Group (FR0000032526 - GBT) has acquired a 39% stake in its share capital through a reserved share capital increase for a total amount of 8.8 million euros at an issuance price of 0.44 euro per share, representing a premium of 34.15% over the last closing price of the shares of Intrasense (the "Capital Increase").

发现更多
订阅